Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.50 |
| ▸ | HTR6 | P50406 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HTR7 | P34969 | 4/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | QDPR | P09417 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24196806 | 0.78 | SIGMAR1 (0.55) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL14085309 | 0.77 | HTR2A (0.32) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL27518176 | 0.76 | SIGMAR1 (0.44) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL13999800 | 0.75 | SIGMAR1 (0.45) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL12895284 | 0.75 | QDPR (0.51) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL25328675 | 0.75 | HTR2C (0.53) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL24671095 | 0.75 | HTR2C (0.44) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL7396564 | 0.74 | HTR6 (0.51) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL532892 | 0.72 | HTR2C (0.66) | HTR2CHTR6HTR2AHTR7SIGMAR1 | |
| SCHEMBL3386020 | 0.72 | SIGMAR1 (0.59) | HTR2CHTR6HTR2AHTR7SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR2C 2910/4885HTR6 3976/4885HTR2A 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.